linvoseltamab

Linvoseltamab is a **fully human BCMAxCD3 bispecific monoclonal antibody** developed by Regeneron for plasma cell disorders, most notably relapsed or refractory multiple myeloma. It is designed to bind **B-cell maturation antigen** on malignant plasma cells and **CD3** on T cells, thereby redirecting T-cell cytotoxicity toward BCMA-expressing myeloma cells. The program was previously known as **REGN5458** and advanced through the Phase 1/2 **LINKER-MM1** study, which supported regulatory filings in heavily pretreated multiple myeloma. Linvoseltamab has also been studied in combinations and in earlier disease settings, including smoldering multiple myeloma, monoclonal gammopathy of undetermined significance, AL amyloidosis, and exploratory non-oncology use in severe IgE-mediated food allergy. In the United States it is marketed as **Lynozyfic**, with the approved product using the nonproprietary name **linvoseltamab-gcpt**.

Brand names

Lynozyfic

Other names

linvoseltamab-gcpt